Schizophrenia is a brain disorder associated with unusual or bizarre thinking or
behavior.
The following are common symptoms associated with schizophrenia:
Hearing things that other people cannot hear, such as noises or the voices of people
whispering or talking
Having the feeling that someone is going out of the way to give you a hard time or
trying to hurt you
Having visions or seeing things that other people cannot see
Feeling that people are talking about you or taking special notice of you
Receiving special messages from the TV, radio or newspaper
Feeling you have special powers to do things that other people cannot do
Having strange sensations in your body or on your skin
Smelling or tasting things that other people cannot smell or taste
Having severe difficulty concentrating and expressing oneself verbally
Acting in ways others see as unusual or bizarre
Withdrawal from normal social, family, and professional relations
Most of the time, the onset of symptoms of schizophrenia occurs during
late adolescence or early adulthood, and each year 100,000 young Americans are diagnosed
with schizophrenia. Once diagnosed, there is a very substantial chance that the patient
may have at least some partial disability for most of his/her life. Medication can greatly
reduce this risk.
Approximately 1% of the American population suffers from schizophrenia, and yet in the
United States, public-funding supports only about $7 per patient per year for
schizophrenia research. (Approximately $150 per patient per year is allocated for cancer
or heart disease research). The contribution of the pharmaceutical industry in finding new
treatments for this devastating illness has been much more substantial.
Schizophrenia is increasingly treated with newer medications that enable a person to
lead a productive life, without many stigmatizing behavioral side effects that plagued
patients on the earlier antipsychotic drugs. Carman Research has actively participated in
development of these newer medications and continues to investigate other candidates of
this class.